JENA, Germany, June 29, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, provided a development update today for its first-in-class monoclonal anti-C5a antibody, vilobelimab, in pyoderma gangrenosum (PG) and severe COVID-19.
Read more at globenewswire.comInflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19
Globe Newswire -
Wed Jun 29, 2022
Columnist
Contributor Content
Press Release
Sponsored Content
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Berskshire%20Hathaway%20Warren%20Buffett%20image%20by%20QubixStudio%20via%20Shutterstock.jpg)
/AI%20(artificial%20intelligence)/Artificial%20intelligence%20and%20machine%20learning%20concept%20-%20by%20amgun%20via%20iStock.jpg)
/Quantum%20Computing/A%20concept%20image%20with%20a%20brain%20on%20top%20of%20a%20blue%20circuit%20board_%20Image%20by%20Gorodenkoff%20via%20Shutterstock_.jpg)
/EV%20in%20showroom%20by%20Robert%20Way%20via%20Shutterstock.jpg)
/Berkshire%20Hathaway%20Inc_%20logo%20on%20phone-by%20FelloeNeko%20via%20Shutterstock.jpg)